Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Avidity Biosciences
(NASDAQ:RNA)
Intraday
$23.55
-0.36
[-1.51%]
After-Hours
$23.55
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$23.55
-0.36
[-1.51%]
At close: Apr 17
$23.55
0
[0.00%]
After Hours: 4:00PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Avidity Biosciences Stock (NASDAQ:RNA)
Avidity Biosciences Stock (NASDAQ: RNA)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, April 11, 2024
Where Avidity Biosciences Stands With Analysts
Benzinga Insights
-
6 days ago
Needham Reiterates Buy on Avidity Biosciences, Maintains $35 Price Target
Benzinga Newsdesk
-
6 days ago
Tuesday, April 02, 2024
Avidity Biosciences Filed Prospectus For Proposed Resale Or Other Disposition By Selling Securityholders Of Up To 15.2M Shares Of Common Stock; Prospectus For Up To 9M Shares Issuable Upon Exercise Of Pre-funded Warrants
Charles Gross
-
Apr 2, 2024, 4:24PM
Thursday, March 14, 2024
Neuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surge
Vandana Singh
-
Mar 14, 2024, 3:29PM
Cantor Fitzgerald Initiates Coverage On Avidity Biosciences with Overweight Rating, Announces Price Target of $60
Benzinga Newsdesk
-
Mar 14, 2024, 7:37AM
Tuesday, March 05, 2024
American Airlines To Rally Around 42%? Here Are 10 Top Analyst Forecasts For Tuesday
Avi Kapoor
-
Mar 5, 2024, 9:30AM
A Closer Look at 5 Analyst Recommendations For Avidity Biosciences
Benzinga Insights
-
Mar 5, 2024, 7:00AM
Chardan Capital Maintains Buy on Avidity Biosciences, Raises Price Target to $33
Benzinga Newsdesk
-
Mar 5, 2024, 5:33AM
Monday, March 04, 2024
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Avi Kapoor
-
Mar 4, 2024, 1:29PM
Needham Reiterates Buy on Avidity Biosciences, Maintains $35 Price Target
Benzinga Newsdesk
-
Mar 4, 2024, 1:10PM
Avidity Biosciences Says Lead Program Shows Reversal Of Disease Progression In Neuromuscular Disease
Vandana Singh
-
Mar 4, 2024, 12:28PM
Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday
Avi Kapoor
-
Mar 4, 2024, 10:40AM
Avidity Biosciences Announced New Long-term AOC 1001 Data From The Marina-OLE Trial Showing Reversal Of Disease Progression In Myotonic Dystrophy Type 1 Patients Across Multiple Endpoints
Benzinga Newsdesk
-
Mar 4, 2024, 7:28AM
Thursday, February 29, 2024
Avidity Biosciences shares are trading higher after the company announced an oversubscribed $400 million private placement.
Benzinga Newsdesk
-
Feb 29, 2024, 2:05PM
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Avi Kapoor
-
Feb 29, 2024, 2:00PM
Hormel Foods Reports Upbeat Earnings, Joins Pure Storage, Okta, Papa John's International And Other Big Stocks Moving Higher On Thursday
Avi Kapoor
-
Feb 29, 2024, 11:30AM
Top 3 Health Care Stocks You May Want To Dump In Q1
Avi Kapoor
-
Feb 29, 2024, 10:40AM
Tech Stocks Set To Rise Thursday As January Inflation Data Fails To Scare Markets, Small Caps Surge
Piero Cingari
-
Feb 29, 2024, 9:20AM
Needham Reiterates Buy on Avidity Biosciences, Maintains $35 Price Target
Benzinga Newsdesk
-
Feb 29, 2024, 8:51AM
Chardan Capital Reiterates Buy on Avidity Biosciences, Maintains $23 Price Target
Benzinga Newsdesk
-
Feb 29, 2024, 8:10AM
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
-
Feb 29, 2024, 8:07AM
Avidity Biosciences Announces $400M Private Placement Of 15.2M Shares At $16.50/Share And Pre-Funded Warrants To Purchase 9.0M Shares At $16.499/Pre Funded Warrant; Pro Forma Cash, Cash Equivalents And Investments Expected To Provide Runway Into Late 2026
Benzinga Newsdesk
-
Feb 29, 2024, 7:09AM
Wednesday, February 28, 2024
Avidity Biosciences Q4 EPS $(0.79) Misses $(0.66) Estimate, Sales $2.19M Down From $2.77M YoY
Happy Mohamed
-
Feb 28, 2024, 4:44PM
Tuesday, February 20, 2024
Avidity Biosciences Receives FDA Rare Pediatric Disease Designation For AOC 1044 For Treatment Of Duchenne Muscular Dystrophy In People With Mutations Amenable To Exon 44 Skipping
Benzinga Newsdesk
-
Feb 20, 2024, 9:01AM
Thursday, February 15, 2024
Avidity Biosciences To Present AOC 1001 Long-Term Efficacy And Safety Data From MARINA-OLE Trial In People Living with Myotonic Dystrophy Type 1 At 2024 Muscular Dystrophy Association Clinical & Scientific Conference
Benzinga Newsdesk
-
Feb 15, 2024, 5:02PM
Friday, January 05, 2024
Avidity Biosciences Plans To Initiate Global Phase 3 HARBOR Trial Of AOC 1001 For DM1 In Mid-2024; Co. To Report Data From All Three Ongoing Programs In 2024
Benzinga Newsdesk
-
Jan 5, 2024, 8:34AM
Wednesday, January 03, 2024
Wells Fargo Reiterates Overweight on Avidity Biosciences, Maintains $50 Price Target
Benzinga Newsdesk
-
Jan 3, 2024, 1:11PM
Wednesday, December 13, 2023
Avidity Biosciences Reports Data Demonstrating AOC 1044 Delivers Unprecedented Concentrations Of PMO In Muscle Following A Single Dose In Healthy Volunteers From Phase 1/2 EXPLORE44 Trial For Duchenne Muscular Dystrophy
Benzinga Newsdesk
-
Dec 13, 2023, 8:42AM
Wednesday, November 29, 2023
Needham Reiterates Buy on Avidity Biosciences, Maintains $35 Price Target
Benzinga Newsdesk
-
Nov 29, 2023, 4:30AM
Tuesday, November 28, 2023
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
-
Nov 28, 2023, 2:44PM
PDD Posts Upbeat Revenue, Joins Avidity Biosciences, SpringWorks Therapeutics And Other Big Stocks Moving Higher On Tuesday
Lisa Levin
-
Nov 28, 2023, 9:39AM
US Stocks Mixed; House Prices Rise In September
Lisa Levin
-
Nov 28, 2023, 9:33AM
Avidity Biosciences shares are trading higher after the company announced an expansion to its cardiovascular collaboration with Bristol Myers Squibb in a $2.3 billion deal. Avidity will receive $100 million up front.
Benzinga Newsdesk
-
Nov 28, 2023, 9:31AM
Why Is RNA Therapeutics-Focused Avidity Biosciences Stock Trading Higher Today?
Vandana Singh
-
Nov 28, 2023, 9:17AM
Market-Moving News for November 28th
Benzinga Newsdesk
-
Nov 28, 2023, 8:45AM
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
-
Nov 28, 2023, 8:06AM
Avidity Biosciences Partners with Bristol Myers Squibb in $2.3B Deal for Cardiovascular RNA Therapeutics, Secures $100M Upfront
Benzinga Newsdesk
-
Nov 28, 2023, 6:45AM
Monday, October 09, 2023
Avidity Biosciences' Muscle Disease Candidate Shows Improvement in Multiple Additional Functional Endpoints, Safety
Vandana Singh
-
Oct 9, 2023, 12:37PM
Why Avidity Biosciences Shares Are Trading Higher By Around 9%: 20 Stocks Moving Premarket
Lisa Levin
-
Oct 9, 2023, 8:20AM
Tuesday, October 03, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Oct 3, 2023, 2:37PM
Wednesday, September 13, 2023
Avidity Biosciences President and CEO Awarded $1.50M Worth of Stock Options
Benzinga Insights
-
Sep 13, 2023, 11:01AM
Avidity Biosciences Chief Financial Officer Awarded $553K Worth of Stock Options
Benzinga Insights
-
Sep 13, 2023, 11:00AM
Monday, September 11, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Sep 11, 2023, 1:38PM
Thursday, September 07, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Sep 7, 2023, 1:55PM
Wednesday, September 06, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Sep 6, 2023, 2:43PM
Tuesday, August 22, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Aug 22, 2023, 1:51PM
Tuesday, August 15, 2023
Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1044 For Treatment Of Duchenne Muscular Dystrophy In People With Mutations Amenable To Exon 44 Skipping
Benzinga Newsdesk
-
Aug 15, 2023, 9:01AM
Monday, August 14, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Aug 14, 2023, 1:48PM
Friday, August 11, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Aug 11, 2023, 2:01PM
Thursday, August 10, 2023
Avidity Biosciences Received FDA Orphan Drug Designation For Treatment of Duchenne Muscular Dystrophy
Charles Gross
-
Aug 10, 2023, 7:41PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch